36 results about "Daunorubicina" patented technology

Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.

The invention discloses a preparation method of a double-targeting acid-sensitive prussian blue drug delivery system and an application thereof, which can effectively solve the problems of leukemia drug resistance and liver and spleen infiltration. According to the technical scheme, the preparation method comprises the following steps: firstly, adsorbing acid-sensitive polyethylene glycol-polyethyleneimine macromolecules on the surfaces of Prussian blue nanoparticles through electrostatic interaction and hydrogen-bond interaction; secondly, the CXCR4 antagonistic polypeptide (E5) and hyaluronic acid are connected with polyethyleneimine molecules on the surfaces of the prussian blue nanoparticles through chemical bonds; thirdly, daunorubicin is adsorbed to the surfaces of the prussian bluenanoparticles through hydrogen bond interaction. The preparation method is simple and mild, materials are safe and easy to obtain, good biocompatibility is achieved, a prepared carrier has the blood long-circulation capacity, the tumor cell double-targeting capacity, the lysosome escape capacity and the acid-sensitive drug release capacity, the mouse leukemia treatment effect can be effectively enhanced, and bone marrow homing and liver and spleen infiltration are inhibited.

The invention relates to a preparation method of a nano delivery system of a double-pH sensitive supported chemotherapy drug daunorubicin (DNR). The preparation method comprises specific steps as follows: DNR and p-alkynyl benzaldehyde react to produce imine-DNR; then, a macromolecular carrier POEGMA-poly(p-azido benzyl methacrylate-co-AMA is prepared, and amphipathic blocks, azido and amino are introduced; alkynyl of the imine-DNA and the azido of the macromolecular carrier are subjected to a click chemical reaction to obtain a DNR polymer predrug intermediate; and amino of the macromolecularpredrug intermediate and 2,3-dimethyl maleic anhydride react to obtain a DNR macromolecular predrug, and self-assembly is carried out to obtain polymeric micelle. The polymeric micelle prepared by the method can realize charge reverse in normal systemic circulation and cancer cell environments according to different pH conditions, improve target property, realize precise delivery of drugs, reducetoxic and side effects of drugs and enhance antitumor therapeutic effects.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.

The invention provides the application of Hsp90 inhibitor 17-DMAG in the preparation of medicines for inhibiting children's acute lymphoblastic leukemia, which belongs to the field of medical biotechnology. Experiments have verified that the combination of Hsp90 inhibitor 17-DMAG and cytarabine can synergistically promote the apoptosis of leukemia cells, but it cannot achieve similar effects when combined with daunorubicin and etoposide. It provides a basis for establishing the rational application of 17-DMAG combined with cytarabine chemotherapy in children ALL chemotherapy, and provides the possibility to improve the chemotherapy effect of leukemia patients and improve drug resistance; The application of DMAG and cytarabine as active ingredients in the preparation of drugs for inhibiting children's acute lymphoblastic leukemia.

The present invention discloses a nucleotide sequence which roots in an anthracycline and produces the partial gene dnrX1 and the gene fragment dnrX 2 of the dnrX 1 of streptomyces coeruleorubidus (Streptomyces coeruleorubidus), and an express vector containing the sequences. The present invention also discloses a gene disruption engineering strain which disrupts the treptomyces coeruleorubidus of the dnrX gene by adopting the express vectors with an exchange and homologous recombination method. When the gene disruption engineering strain is used to produce the anthracycline, the acidizing treatment is not required, adriacin which is not produced by a wild fungus can be produced, and the output of the adriacin and the daunorubicin can be greatly increased.

This invention relates to methods and compositions for treatment of inv(16) leukemia and particularly to treatment of acute myeloid leukemia. Disclosed is a method of treating inv(16) leukemia comprising the step of administering to a subject in need thereof a therapeutically effective combination of a) a compound of the formula (1) and b) a chemotherapeutic agent selected from the group consisting of pirarubicin, aclarubicin, mitoxantrone, doxorubicin, daunorubicin, idarubicin, epirubicin, cytarabine, pharmaceutically acceptable salts and mixtures thereof. The therapeutically effective combination synergistically inhibits proliferation of inv(16) leukemia cells. This invention also relates to pharmaceutical compositions comprising a therapeutically effective combination of the compound of formula (1) and the chemotherapeutic agent and a pharmaceutically acceptable excipient.

Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium (Amycolatopsis orientalis) are substituted with another amino acid residues.

This invention discloses a genetically engineered strain of streptomyces coeruleorubidus highly producing epi-daunorubicin, which is a genetically engineered strain to block dnmV gene and express aveBIV (avermectins keto-reductase) by inserting a first foreign gene containing aveBIV gene in the dnmV gene of a wild strain of the streptomyces coeruleorubidus or changing the dnmV gene of the wild strain of the streptomyces coeruleorubidus into the first foreign gene containing aveBIV gene. A second foreign gene is further integrated in the genome of the genetically engineered strain, and the first and second foreign genes are chain segments of a promoter and the aveBIV gene. The constructed genetically engineered strain does not contain any resistance marker and is convenient for further genetic engineering construction. The yield of epi-daunorubicin is preferably 70mg / L and is far greater than that of the epi-daunorubicin made by existing methods; through continuous passage, the yield of epi-daunorubicin is very stable with good repeatability.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.

The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison. A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.

The invention discloses a preparation method and application of a dual-target acid-sensitive Prussian blue drug-carrying system, which can effectively solve the problems of leukemia drug resistance and liver and spleen infiltration. The technical solution is, firstly, the acid-sensitive polyethylene glycol-polyethyleneimine polymer is adsorbed on the surface of Prussian blue nanoparticles through electrostatic and hydrogen bonding; secondly, CXCR4 antagonistic polypeptide (E5) and hyaluronic acid are chemically bonded to Polyethyleneimine molecules on the surface of Prussian blue nanoparticles are connected; again, daunorubicin is adsorbed on the surface of Prussian blue nanoparticles through hydrogen bonding. The preparation method of the present invention is simple and mild, the material is safe and easy to obtain, and has good biocompatibility. The prepared carrier has long-term blood circulation ability, tumor cell double-targeting ability, lysosome escape ability, and acid-sensitive drug release ability, and can effectively Enhance the therapeutic effect of leukemia in mice and inhibit the homing of bone marrow and the infiltration of liver and spleen.

The invention discloses a gene blocking mutant for streptomyces coeruleorubidus and a preparation method thereof. In the gene blocking mutant for streptomyces coeruleorubidus, a dauW gene is blocked. In the technical scheme, the dauW gene in streptomyces coeruleorubidus is blocked through homologous recombination exchange, the yield of daunorubicin of streptomyces coeruleorubidus is greatly improved after the dauW gene is blocked and has increased by five times, and the effect is much better than that of blocking other genes, e.g. dnrX, dnrH and the like, the yield of which only can be increased by three times. Therefore, the blocking of the dauW gene substantially improves the fermentation unit of daunorubicin.

The application of the invention provides a daunorubicin-containing medicine, a preparation method of the daunorubicin-containing medicine, a medical composition and an application of the daunorubicin-containing medicine. The medicine comprises nucleic acid nanometer particles and daunorubicin, wherein the daunorubicin is mounted on the nucleic acid nanometer particles, the nucleic acid nanometerparticles comprise nucleic acid structural domains, the nucleic acid structural domains include an a sequence, a b sequence and a c sequence, the a sequence includes an a1 sequence or a sequence obtained in a manner that one or more basic groups of the a1 sequence are inserted, deleted or replaced, the b sequence includes a b1 sequence or a sequence obtained in a manner that one or more basic groups of the b1 sequence are inserted, deleted or replaced, and the c sequence includes a c1 sequence or a sequence obtained in a manner that one or more basic groups of the c1 sequence are inserted, deleted or replaced. According to the daunorubicin-containing medicine provided by the application of the invention, after the nucleic acid structural domains are subjected to target head modification, the daunorubicin-containing medicine has better target properties, can steadily deliver the daunorubicin, and is high in reliability.

The present invention relates to a preparation method of magnetic nano medicine for curing leukemia. Said preparation method uses surface-functional monodisperse magnetic nano particle Ni or Fe2O3 or Fe3O4 as carrier, on the surface of carrier the doxorubicin or daunorubicin or other medicine for curing leukemia can be loaded. Under the condition of externally-applied magnetic field it can be used for making auxiliary therapy, and can greatly raise medicine concentration in leukemia cell interior of tumor zone, and can reduce the hazard due to medicine resistance of cell to obtain the action of controlling and effectively killing cancer cell.